If This Trend Holds, I’ll Trade It. - InvestingChannel

If This Trend Holds, I’ll Trade It.

Nothing gets me more excited than a brand new week of trading opportunities to be made alongside financial professional insight.

Today I’ve outlined a trading opportunity which I believe could lead to profit, and I’ve prepared an exclusive report for you.

Ticker Code Ticker Name Ticker Industry Price Change Average Volume (50)*
NBIX Neurocrine Biosciences Inc Biotechnology 3.81% 819,896
OPGN Opgen Inc Diagnostics & Research -22.60% 887,300
ZOM Zomedica Pharmaceuticals Corp Drug Manufacturers – Specialty & Generic 24.00% 32,831,401
SCYX Scynexis Inc Drug Manufacturers – Specialty & Generic 7.14% 1,142,561
TUES Tuesday Morning Corp Discount Stores -107.14% 1,637,651
ROKU Roku Inc Pay TV 33.82% 12,781,878
TXMD TherapeuticsMD Inc Drug Manufacturers – Specialty & Generic 19.08% 5,664,626
HHT China Advanced Construction Materials Group Inc Building Materials -22.22% 891,906
MVIS Microvision Inc Scientific & Technical Instruments 8.87% 33,818,165
ONTX Onconova Therapeutics Inc Biotechnology 16.67% 5,015,068
TRPX Therapix Biosciences Ltd Biotechnology -4.88% 2,836,328
GOOG Kitov Pharma Ltd Internet Content & Information 17.14% 2,127,956
KTOV Alphabet Inc Biotechnology 36.73% 11,687,819
AAPL Fuelcell Energy Inc Consumer Electronics 1.57% 39,573,757
FCEL Apple Inc Electrical Equipment & Parts 26.70% 8,386,688
MARK Remark Holdings Inc Internet Content & Information 72.12% 26,083,328
AMZN Amazon Com Inc Internet Retail 1.24% 5,629,197
SQBG Sequential Brands Group Inc Apparel Manufacturing 12.50% 962,584
TTNP Titan Pharmaceuticals Inc Biotechnology 28.13% 8,310,046
V Visa Credit Services -0.83% 14,335,145

While we have heard some rumors of the economy reviving, reopening venues and destinations will come with risk, extensive safety measures, and speculation.

One headline remains consistent time and time again… In order to reopen an economy which has been slashed as a result of the coronavirus pandemic, we need a vaccine which passes tests positive, and is effective as well.

Neither of those will be easy to complete successfully – and definitely won’t happen overnight.

There is, however, one company which financial professionals and even the talking heads on television remain optimistic on to be the company which officially releases an effective vaccine, is capable of helping mass amounts of individuals, and ideally results in the economy being able to reopen in full.

Gilead Sciences (NYSE: GILD) might be the only stock which went up during March’s epic stock market selloff.


In the eyes of financial professionals and politicians, Gilead may be the first company to develop, test, and release an effective vaccine – which at this point is pretty much a necessity in order to reopen the economy.

In the eyes of a trader, not only does this catalyst bring optimism to Gilead’s stock itself, it is also creating an easy to read trading trend, which I’ll be looking for today and through this week – as I expect financial professionals to be doing the exact same…

In the chart above you’ll notice Gilead’s 50-day simple moving average line in red. Should Gilead trade above its 50-day simple moving average line, I’ll be interested in making a bullish trade, and collecting quick profits.

With an optimistic catalyst in place and a clear technical trading plan laid out, I expect Gilead to make for a nice and easy trade, and who doesn’t love easy.

Yours for TrackStar trading,

Davis Martin
America’s #1 Premarket and Day Trader

Disclaimer: This is not investment advice. This article is for information purposes only and opinion-based on financial advisor data across a selection of websites. Investors should be cautious about any and all investments and are advised to conduct their own due diligence prior to making any investment decisions.

Related posts

Peers Reducing Beta in Uncertain Times


Can this Stock Ease Your Stress?


Advisors Looking East and Going for Gold


Market Showing Some Crox


Tech Earnings, Elections and Covid Oh My!


Commodities at the Forefront as Elections Loom